Anti-CEA CAR-T cells therapy (Sorrento Therapeutics)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CEA CAR-T cells therapy (Sorrento Therapeutics)
Drug Alias NameAnti-CEA CAR-TCAR-T CEACEA CARTAnti-CEA T-cellsCAR-T CEA-therapy +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CEA
TargetsCarcinoembryonic antigen
Therapy Area/IndicationsPancreatic NeoplasmsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics IncShenyang Sunshine Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSorrento Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLiver Neoplasms
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A